---
document_datetime: 2025-12-25 07:00:38
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/minjuvi.html
document_name: minjuvi.html
version: success
processing_time: 0.0984915
conversion_datetime: 2025-12-28 15:02:42.508595
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Minjuvi

[RSS](/en/individual-human-medicine.xml/67472)

##### Authorised

This medicine is authorised for use in the European Union

tafasitamab Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Minjuvi](#news-on)
- [More information on Minjuvi](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Minjuvi is a cancer medicine used first in combination with another medicine called lenalidomide, and then on its own, to treat adults with diffuse large B-cell lymphoma (DLBCL) whose cancer has returned or has stopped responding to other treatments and who cannot have an autologous stem cell transplantation (a transplant where the stem cells are collected from the patients themselves).

DLBCL is rare, and Minjuvi was designated an 'orphan medicine' (a medicine used in rare diseases) on 15 January 2015. Further information on the orphan designation can be found [here](/en/medicines/human/orphan-designations/eu-3-14-1424) .

Minjuvi contains the active substance tafasitamab.

Expand section

Collapse section

## How is Minjuvi used?

Minjuvi can only be obtained with a prescription and must be given by a healthcare professional experienced in cancer treatment. The medicine is available as a powder to be made into a solution for infusion (drip) into a vein.

Minjuvi treatment is given over cycles of 28 days, with the infusion given on certain days of each cycle. The dose is based on body weight. The doctor may adjust or stop treatment based on the patient's reaction to the infusion. Minjuvi is given with lenalidomide for up to 12 cycles, after which Minjuvi can be given alone. Treatment continues until the disease progresses or side effects become unacceptable.

Patients are also given medicines to reduce the risk of reactions to the infusion before each dose of Minjuvi, for at least the first 3 infusions. Any infection should be treated before starting treatment with Minjuvi.

For more information about using Minjuvi, see the package leaflet or contact your doctor or pharmacist.

## How does Minjuvi work?

The active substance in Minjuvi, tafasitamab, is a monoclonal antibody, a type of protein that is designed to recognise and attach to a specific structure on certain cells in the body. Tafasitamab in particular, was designed to attach to CD19, a protein that is present on the surface of the cancer cells. When attached to CD19, the medicine is expected to stimulate the immune system (the body's natural defences) to attack and kill the cancer cells and thereby slow down the progression of the disease.

## What benefits of Minjuvi have been shown in studies?

Minjuvi used in combination with lenalidomide was investigated in a study involving 81 adult patients with DLBCL that did not respond to other treatments and who could not have an autologous stem cell transplantation. In this study, patients were treated with Minjuvi and lenalidomide for up to 12 cycles followed by Minjuvi on its own until the disease progressed or side effects became unmanageable. Of the patients involved in the study, 46 (57%) had either a complete response (no sign of cancer) or a partial response.

## What are the risks associated with Minjuvi?

The most common side effects with Minjuvi (which may affect more than 1 in 10 people) are infections, neutropenia (low white blood cell count), anaemia (low red blood cell count), thrombocytopaenia (low blood platelet count), diarrhoea, weakness, cough, peripheral oedema (swelling especially of the ankles and feet), fever and decreased appetite.

The most common serious side effects (which may affect more than 1 in 100 people) are infection, including pneumonia (infection of the lungs), and neutropenia with fever.

For the full list of side effects and restrictions with Minjuvi, see the package leaflet.

## Why is Minjuvi authorised in the EU?

Patients with DLBCL whose cancer has returned or does not respond to treatment and who cannot have an autologous stem cell transplantation have limited treatment options. Minjuvi together with lenalidomide was shown to provide a clinically meaningful response and the side effects were manageable. The European Medicines Agency therefore decided that Minjuvi's benefits are greater than its risks and it can be authorised for use in the EU.

Minjuvi has been given 'conditional authorisation'. This means that there is more evidence to come about the medicine, which the company is required to provide. Every year, the European Medicines Agency will review any new information that becomes available and this overview will be updated as necessary.

## What information is still awaited for Minjuvi?

Since Minjuvi has been given conditional authorisation, the company that markets Minjuvi will provide evidence from three additional studies on the safety and efficacy of the medicine in combination with lenalidomide or bendamustine (another cancer medicine) in patients with DLBCL.

## What measures are being taken to ensure the safe and effective use of Minjuvi?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Minjuvi have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Minjuvi are continuously monitored. Side effects reported with the medicine are carefully evaluated and any necessary action taken to protect patients.

## Other information about Minjuvi

Minjuvi received a conditional marketing authorisation valid throughout the EU on 26 August 2021.

Minjuvi : EPAR - Medicine overview

English (EN) (121.86 KB - PDF)

**First published:** 08/09/2021

[View](/en/documents/overview/minjuvi-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-748)

български (BG) (136.19 KB - PDF)

**First published:**

08/09/2021

[View](/bg/documents/overview/minjuvi-epar-medicine-overview_bg.pdf)

español (ES) (120.63 KB - PDF)

**First published:**

08/09/2021

[View](/es/documents/overview/minjuvi-epar-medicine-overview_es.pdf)

čeština (CS) (142.18 KB - PDF)

**First published:**

08/09/2021

[View](/cs/documents/overview/minjuvi-epar-medicine-overview_cs.pdf)

dansk (DA) (118.67 KB - PDF)

**First published:**

08/09/2021

[View](/da/documents/overview/minjuvi-epar-medicine-overview_da.pdf)

Deutsch (DE) (123.02 KB - PDF)

**First published:**

08/09/2021

[View](/de/documents/overview/minjuvi-epar-medicine-overview_de.pdf)

eesti keel (ET) (108.53 KB - PDF)

**First published:**

08/09/2021

[View](/et/documents/overview/minjuvi-epar-medicine-overview_et.pdf)

ελληνικά (EL) (146.77 KB - PDF)

**First published:**

08/09/2021

[View](/el/documents/overview/minjuvi-epar-medicine-overview_el.pdf)

français (FR) (121.93 KB - PDF)

**First published:**

08/09/2021

[View](/fr/documents/overview/minjuvi-epar-medicine-overview_fr.pdf)

hrvatski (HR) (143.87 KB - PDF)

**First published:**

08/09/2021

[View](/hr/documents/overview/minjuvi-epar-medicine-overview_hr.pdf)

italiano (IT) (119.69 KB - PDF)

**First published:**

08/09/2021

[View](/it/documents/overview/minjuvi-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (151.14 KB - PDF)

**First published:**

08/09/2021

[View](/lv/documents/overview/minjuvi-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (143.25 KB - PDF)

**First published:**

08/09/2021

[View](/lt/documents/overview/minjuvi-epar-medicine-overview_lt.pdf)

magyar (HU) (143.01 KB - PDF)

**First published:**

08/09/2021

[View](/hu/documents/overview/minjuvi-epar-medicine-overview_hu.pdf)

Malti (MT) (144.65 KB - PDF)

**First published:**

08/09/2021

[View](/mt/documents/overview/minjuvi-epar-medicine-overview_mt.pdf)

Nederlands (NL) (119.39 KB - PDF)

**First published:**

08/09/2021

[View](/nl/documents/overview/minjuvi-epar-medicine-overview_nl.pdf)

polski (PL) (145 KB - PDF)

**First published:**

08/09/2021

[View](/pl/documents/overview/minjuvi-epar-medicine-overview_pl.pdf)

português (PT) (121.19 KB - PDF)

**First published:**

08/09/2021

[View](/pt/documents/overview/minjuvi-epar-medicine-overview_pt.pdf)

română (RO) (142.01 KB - PDF)

**First published:**

08/09/2021

[View](/ro/documents/overview/minjuvi-epar-medicine-overview_ro.pdf)

slovenčina (SK) (141.74 KB - PDF)

**First published:**

08/09/2021

[View](/sk/documents/overview/minjuvi-epar-medicine-overview_sk.pdf)

slovenščina (SL) (142.41 KB - PDF)

**First published:**

08/09/2021

[View](/sl/documents/overview/minjuvi-epar-medicine-overview_sl.pdf)

Suomi (FI) (117.42 KB - PDF)

**First published:**

08/09/2021

[View](/fi/documents/overview/minjuvi-epar-medicine-overview_fi.pdf)

svenska (SV) (119.56 KB - PDF)

**First published:**

08/09/2021

[View](/sv/documents/overview/minjuvi-epar-medicine-overview_sv.pdf)

Minjuvi : EPAR - Risk management plan

English (EN) (539.15 KB - PDF)

**First published:** 08/09/2021

**Last updated:** 24/10/2025

[View](/en/documents/rmp/minjuvi-epar-risk-management-plan_en.pdf)

## Product information

Minjuvi : EPAR - Product information

English (EN) (207.31 KB - PDF)

**First published:** 08/09/2021

**Last updated:** 19/12/2025

[View](/en/documents/product-information/minjuvi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-441)

български (BG) (352.89 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/bg/documents/product-information/minjuvi-epar-product-information_bg.pdf)

español (ES) (236.41 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/es/documents/product-information/minjuvi-epar-product-information_es.pdf)

čeština (CS) (310.66 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/cs/documents/product-information/minjuvi-epar-product-information_cs.pdf)

dansk (DA) (212.35 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/da/documents/product-information/minjuvi-epar-product-information_da.pdf)

Deutsch (DE) (230.21 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/de/documents/product-information/minjuvi-epar-product-information_de.pdf)

eesti keel (ET) (279.22 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/et/documents/product-information/minjuvi-epar-product-information_et.pdf)

ελληνικά (EL) (336.67 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/el/documents/product-information/minjuvi-epar-product-information_el.pdf)

français (FR) (225.99 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/fr/documents/product-information/minjuvi-epar-product-information_fr.pdf)

hrvatski (HR) (304.71 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/hr/documents/product-information/minjuvi-epar-product-information_hr.pdf)

íslenska (IS) (211.54 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/is/documents/product-information/minjuvi-epar-product-information_is.pdf)

italiano (IT) (220.12 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/it/documents/product-information/minjuvi-epar-product-information_it.pdf)

latviešu valoda (LV) (320.56 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/lv/documents/product-information/minjuvi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (311.3 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/lt/documents/product-information/minjuvi-epar-product-information_lt.pdf)

magyar (HU) (327.97 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/hu/documents/product-information/minjuvi-epar-product-information_hu.pdf)

Malti (MT) (359.76 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/mt/documents/product-information/minjuvi-epar-product-information_mt.pdf)

Nederlands (NL) (226.39 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/nl/documents/product-information/minjuvi-epar-product-information_nl.pdf)

norsk (NO) (235.4 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/no/documents/product-information/minjuvi-epar-product-information_no.pdf)

polski (PL) (359.77 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/pl/documents/product-information/minjuvi-epar-product-information_pl.pdf)

português (PT) (213.79 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/pt/documents/product-information/minjuvi-epar-product-information_pt.pdf)

română (RO) (345.76 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/ro/documents/product-information/minjuvi-epar-product-information_ro.pdf)

slovenčina (SK) (323.05 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/sk/documents/product-information/minjuvi-epar-product-information_sk.pdf)

slovenščina (SL) (512.45 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/sl/documents/product-information/minjuvi-epar-product-information_sl.pdf)

Suomi (FI) (215.69 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/fi/documents/product-information/minjuvi-epar-product-information_fi.pdf)

svenska (SV) (218.63 KB - PDF)

**First published:**

08/09/2021

**Last updated:**

19/12/2025

[View](/sv/documents/product-information/minjuvi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000310661 18/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Minjuvi : EPAR - All authorised presentations

Adopted

English (EN) (15.7 KB - PDF)

**First published:** 08/09/2021

[View](/en/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-325)

български (BG) (92.34 KB - PDF)

**First published:**

08/09/2021

[View](/bg/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_bg.pdf)

español (ES) (14.8 KB - PDF)

**First published:**

08/09/2021

[View](/es/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (90.51 KB - PDF)

**First published:**

08/09/2021

[View](/cs/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (14.7 KB - PDF)

**First published:**

08/09/2021

[View](/da/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (14.88 KB - PDF)

**First published:**

08/09/2021

[View](/de/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (14.43 KB - PDF)

**First published:**

08/09/2021

[View](/et/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (89.21 KB - PDF)

**First published:**

08/09/2021

[View](/el/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_el.pdf)

français (FR) (48.22 KB - PDF)

**First published:**

08/09/2021

[View](/fr/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (87.4 KB - PDF)

**First published:**

08/09/2021

[View](/hr/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (12.89 KB - PDF)

**First published:**

08/09/2021

[View](/is/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (14.55 KB - PDF)

**First published:**

08/09/2021

[View](/it/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (89.17 KB - PDF)

**First published:**

08/09/2021

[View](/lv/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (88.46 KB - PDF)

**First published:**

08/09/2021

[View](/lt/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (49.25 KB - PDF)

**First published:**

08/09/2021

[View](/hu/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (89.13 KB - PDF)

**First published:**

08/09/2021

[View](/mt/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (14.2 KB - PDF)

**First published:**

08/09/2021

[View](/nl/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (14.73 KB - PDF)

**First published:**

08/09/2021

[View](/no/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_no.pdf)

polski (PL) (90.21 KB - PDF)

**First published:**

08/09/2021

[View](/pl/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_pl.pdf)

português (PT) (14.86 KB - PDF)

**First published:**

08/09/2021

[View](/pt/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_pt.pdf)

română (RO) (88.19 KB - PDF)

**First published:**

08/09/2021

[View](/ro/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (90.77 KB - PDF)

**First published:**

08/09/2021

[View](/sk/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (88.11 KB - PDF)

**First published:**

08/09/2021

[View](/sl/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (14.55 KB - PDF)

**First published:**

08/09/2021

[View](/fi/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (14.72 KB - PDF)

**First published:**

08/09/2021

[View](/sv/documents/all-authorised-presentations/minjuvi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Minjuvi Active substance tafasitamab International non-proprietary name (INN) or common name tafasitamab Therapeutic area (MeSH) Lymphoma, Large B-Cell, Diffuse Anatomical therapeutic chemical (ATC) code L01FX12

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

## Authorisation details

EMA product number EMEA/H/C/005436

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Incyte Biosciences Distribution B.V.

Paasheuvelweg 25

Opinion adopted 24/06/2021 Marketing authorisation issued 26/08/2021 Revision 10

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Minjuvi : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (147.56 KB - PDF)

**First published:** 06/10/2025

**Last updated:** 19/12/2025

[View](/en/documents/procedural-steps-after/minjuvi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Minjuvi : EPAR - Procedural steps taken and scientific information after the authorisation (archive)

English (EN) (130.07 KB - PDF)

**First published:** 05/10/2021

**Last updated:** 06/10/2025

[View](/en/documents/procedural-steps-after/minjuvi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Minjuvi : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMADOC-1700519818-708261 Corr.

English (EN) (764.99 KB - PDF)

**First published:** 08/09/2021

**Last updated:** 20/12/2021

[View](/en/documents/orphan-maintenance-report/minjuvi-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Minjuvi : EPAR - Public assessment report

Adopted

Reference Number: EMA/426468/2021

English (EN) (6.45 MB - PDF)

**First published:** 08/09/2021

[View](/en/documents/assessment-report/minjuvi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Minjuvi

Adopted

Reference Number: EMA/CHMP/314017/2021

English (EN) (149.59 KB - PDF)

**First published:** 25/06/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-minjuvi_en.pdf)

#### News on Minjuvi

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 November 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-november-2025) 14/11/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-june-2021) 25/06/2021

#### More information on Minjuvi

- [EU/3/14/1424 - orphan designation for treatment of diffuse large B-cell lymphoma](/en/medicines/human/orphan-designations/eu-3-14-1424)
- [EMEA-002499-PIP03-24 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002499-pip03-24)
- [Minjuvi - opinion on variation to marketing authorisation](/en/medicines/human/variation/minjuvi)

**This page was last updated on** 19/12/2025

## Share this page

[Back to top](#main-content)